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Abstract 
A structure activity model which incorporates the desolvation, lipophilicity, dipole moment 
and molecular volume of a series of modafinil like analogues has been compared to a series 
of saturated heterocyclic analogues in their ability to inhibit the dopamine transporter (DAT). 
It has been found that hydrophilicity or lipophilicity has a larger inhibitory effect for the 
heterocyclic analogues than the modafinil like analogues, but the heterocyclic inhibitors show 
no dependence on dipole moment unlike the modafinil like analogues. The modafinil like 
analogues have a higher desolvation requirement than the heterocyclic analogues prior to 
binding with DAT as expected for the more polar structures. 
 
Evidence is presented that strongly implicates the involvement of free radical species in the 
eugeroic ability of modafinil like and 9-fluorene analogues via a dissociative electron 
attachment mechanism. This eugeroic ability is largely separate from a DAT inhibition 
mechanism. 
 
Introduction 
The neurotransmitter dopamine (DA) determines many body functions including cognition, 
mood, movement, and reward. The levels of DA in the brain is modulated by the dopamine 
transporter (DAT), which is a plasma membrane protein that actively transfers released DA 
from the extracellular space into the presynaptic neuron. The DAT is a target for addictive 
drugs including cocaine, amphetamines and for drugs prescribed for the treatment of attention 
deficit hyperactivity disorder (ADHD), depression, and other dopamine imbalance diseases 
such as Parkinson’s disease, Alzheimer’s disease, bipolar disorder, depression and 
alcoholism. Cocaine binds to the protein and inhibits transport, while amphetamines are 
transported and stimulate reverse transport (efflux) of intracellular DA. Other related drugs 
include nocaine (CPCA) originally developed as a less potent substitute for cocaine, and 
modafinil (Provigil or Nuvigil) a wake promoting agent used for the treatment of narcolepsy. 
A number of comprehensive studies have examined the structure activity relationships of 
modafinil analogues with the DAT. [1-4][Zhou 2004, Cao 2011, 2016, Kalaba 2017] 
DAT belongs to the SLC6 family of transporters that couple inward solute transport to 
downhill movement of Na
+
 and Cl
−
. It is thought that Na
+
 ions bind to the extracellular 
domain of the transporter before dopamine can bind. After dopamine binds, the protein 
undergoes a conformational change, which allows both sodium and dopamine to unbind on 
the intracellular side of the membrane. [5][Sonders 1997]  
While many drugs are routinely used to treat DA disorders, there is no clear consensus about 
the mechanism of how these drugs affect the action of DAT. In particular the mechanism of 
how modafinil exerts its wake-promoting effect is controversial. Modafinil is known to 
weakly but selectively bind with DAT and exert its eugeroic effect by disrupting the transport 
effect of DAT and hence raising extracellular concentrations of DA, which results in 
wakefulness. Modafinil is thus thought to be a dopamine reuptake inhibitor. DAT knockout 
mice are known to be unresponsive to modafinil. [6,7][Wisor 2001, 2013]  However, there is 
significant evidence that the eugeroic action of modafinil includes other processes beside 
acting as a dopamine reuptake inhibitor. For example, a structure activity study of modafinil 
analogues found that DAT inhibition did not correlate with wakefulness-promoting effects in 
animals, and a number of analogues without any significant inhibition of the DAT still 
produced wakefulness-promoting effects. [8,9][Dunn 2012] Other possible mechanisms for 
the eugeroic effect besides the dopamine reuptake inhibition include activation of the orexin 
system. [10][Mereu 2013] 
However there is also evidence that free radicals may be related to sleep induction as well as 
cellular damage, and that modafinil has the ability to oppose both of these effects. It is 
thought that modafinil could directly act on enzymes in the brain’s free-radical scavenging 
system (eg. glutathione peroxidase or superoxide dismutase) and hence directly reduce free-
radical levels. This may account for modafinil’s known ability to increase the 
cortical creatine-phosphocreatine pool. Cytochrome enzymes in the inner mitachrondrial 
membrane transport chain may be involved with modafinil’s electron accepting ability from 
superoxide species in this environment. Modifinil is known to suppress the CYP2C9 enzyme 
and hence reactive oxygen species in the brain, and hence possibly promoting better 
mitachrondrial function and wakefulness. [11][[Gerrard 2007] There is evidence that 
modifinil causes oxidative damage in the amygdala, hippocampus, and striatum of rats at 
high doses. [12][Ornell 2014] 
 
A meta analysis of published studies on sleep deprivation and oxidative stress in the brain 
was used to test the hypothesis that that sleep is a dynamic-resting state with antioxidative 
properties. Wakefulness is thought to involve high neuronal metabolism and neuronal 
electrical potentials, and requires high oxygen levels, and therefore oxidants. Sleep is a state 
with an increased antioxidant activity which promotes a brain protection against free radicals 
by lowering oxidant production. ROS and other oxidative stress markers can accumulate in 
the brain during wakefulness, and so behave as sleep promoters. [13][Villafuerte 2015]  
 
We have previously developed a structure activity model that has been shown to apply to the 
transport and anti-cancer and metabolic efficacy of various drugs. The four parameter general 
model is based on establishing linear free energy relationships between the four drug 
molecular properties and various biological processes. The equation has been previously 
applied to passive and facilitated diffusion of a wide range of drugs crossing the blood brain 
barrier, the active competitive transport of tyrosine kinase inhibitors by the hOCT3, 
OATP1A2 and OCT1 transporters, cyclin-dependent kinase inhibitors and HIV-1 protease 
inhibitors, and the penetration of drugs into tumours.  The model also applies to PARP 
inhibitors, the anti-bacterial and anti-malarial properties of fluoroquinolones, and active 
organic anion transporter drug membrane transport, and some competitive statin-CYP 
enzyme binding processes. There is strong independent evidence from the literature that 
ΔGdesolvation, ΔGlipophilicity/hydrophobicity, the dipole moment and molecular volume are good 
inherent indicators of the transport or binding ability of drugs. As such the model differs from 
docking studies or molecular dynamic studies of the inhibitor-transporter interaction, in that 
the model represents how the inhibitor-ligand undergoes (de)solvation (within the transporter 
environment) just prior to the actual binding interaction but after the inhibitor leaves the bulk 
solvent. The model allows the prediction of new analogues in a structure activity series using 
easily available quantum mechanical molecular properties and allows insights into molecular 
mechanisms. [14-20][Fong 2015-17] 
 
Study objectives:  
Apply the previously developed structure activity model to two widely different series of 
modafinil analogs using available literature DAT inhibitor data to gain mechanistic insights 
into the inhibitory process and possibly the wakefulness promotion processes. 
Investigate whether modafinil could be involved in free radical processes when exerting its 
eugeroic effect. 
 
Results 
 
(a) Structure activity DAT inhibitory models of modafinil analogues 
 
Table 1 shows the structures of the substituted modifinil like analogue series of Cao 2011, [2] 
and Table 2 shows the substituted heterocyclic piperidine analogues series of Zhou 2004 [1] 
Table 3 shows the DAT binding data and their calculated -ΔGdesolv,CDS (free energy of 
desolvation in water, as calculated by ΔGCDS,w), ΔGlipo,CDS (free energy of lipophilicity or 
hydrophobicity in n-octane, as calculated by ΔGCDS,O), DM (dipole moment in water), Volume 
(molecular volume in water) for the two series of DAT inhibitors. 
 
The DAT binding data has been analysed according to the equations below which has been 
previously shown to apply to a wide range of transport or binding of drugs to proteins, and in 
particular transport of drugs across the blood brain barrier:  
 
The free energy of water desolvation (ΔGdesolv,CDS) and the lipophilicity free energy 
(ΔGlipo,CDS) where CDS represents the non-electrostatic first solvation shell solvent 
properties. These molecular properties may be a better approximation of the cybotactic 
environment around the drug approaching or within the protein receptor pocket, or the cell 
membrane surface or the surface of a drug transporter, than the bulk water environment 
outside the receptor pocket or cell membrane surface. The CDS includes dispersion, 
cavitation, and covalent components of hydrogen bonding, hydrophobic effects. Desolvation 
of water from the drug (ΔGdesolv,CDS) before binding in the receptor pocket is required, and 
hydrophobic interactions between the drug and protein (ΔGlipo,CDS) is a positive contribution 
to binding. ΔGlipo,CDS is calculated from the solvation energy in n-octane. 
 
Application of the general equation to the 20 DAT modafinil analogues gives the following 
equation 1, where the molecular volumes have been multiplied by 0.03 to normalize the 
volumes to being similar in magnitude to the other three independent variables to allow direct 
comparison of the relative contributions of the variables. 
                                                                                                                               Eq 1 
DAT Binding = -4604.8 ΔGdesolv,CDS -4588.9 ΔGlipo,CDS -3244.1 DM -2668.9 Vol -26413.5 
Where R2  = 0.518, SEE = 8332, SE(ΔGdesolvCDS) = 1687.8, SE(ΔGlipoCDS) = 1.413.2, SE(Dipole Moment) = 1679.4, SE(Vol) 
= 1379.2, F=4.022, Significance=0.020 
 
Analysis of the 26 heterocyclic piperidine analogues gave equation 2 (after omitting 
modafinil, cocaine, and Z4, Z17D, Z17F, and Z19 as large outliers, and normalizing the 
volumes by 0.03.  
                                                                                                                                 Eq 2 
 DAT Binding = 23.2 ΔGdesolv,CDS +35.6 ΔGlipo,CDS +24.4 Vol +291.6 
Where R
2  
= 0.250, SEE = 86.3, SE(ΔGdesolvCDS) = 21.1, SE(ΔGlipoCDS) = 18.2, SE(Vol) = 23.5, F=2.44, 
Significance=0.090 
 
Eq 2 is a fairly poor precision equation, compared to eq 1, and particularly shows no 
correlation with dipole moment, with the lipophilicity coefficient being the most significant, 
and the desolvation and volume coefficients of lower significance and relative importance. 
Most notable is the change of signs for dependence on lipophilicity (and desolvation and 
volume) between eqs 1 and 2, and no dependence on dipole moment for the piperidine 
analogues in eq 2.    
(b) Free radical eugeroic mechanism of modafinil analogues 
 
The possibility of modafinil exerting its eugeroic effect by a free radical mechanism has been 
investigated by examining the behaviour of modafinil after attachment of an electron in 
water. This bioreduction process may arise in the brain from superoxide species and or 
mitochondrial sources or cytochrome sources. The anion radical formed from the attachment 
of an electron to modafinil is shown to exhibit extension and then cleavage of the 
diphenylmethyl carbon to sulphoxide (C---S) bond, as shown in the transition state in Figure 
1. This dissociative electron attachment reaction [21,22][Malan 2002, Saveant 1994] also 
occurs in the substituted modafinil analogues (C6H4X)2-CH-S(=O)-Z and is driven by the 
delocalized resonance stabilization of the excess electron over the (C6H4X)2-CH-S(=O)- 
moiety in the HOMO. There is a decrease of negative charge on the benzylic (C6H5)2-CH- 
atom and a decrease of positive charge on the S atom when elongation of the C---S bond 
occurs upon the attachment of an electron to modifinil in water. The free energy of activation 
ΔG
*
 for the water solvated modafinil transition state shown in Figure 1 is estimated to be 
about -30 kcal/mol assuming a ΔG for the hydrated electron of -34.6 kcal/mol. [23][Zhan 
2003]  
Figure 1. Transition state for dissociative electron attachment of Modafinil in water
 
Examination of the analogue (11B in Table 3) 
piperazine-1N)-CH2-CH(OH)
2.5 nM) [3][Cao 2016] compared to modafinil (
upon electron attachment as that for modafinil. 
(C6H4X)2-CH-S(=O)-CH2-C(=O)NH
elongation upon electron attachment
Figure 2  
 
Another analogue which shows quite different behaviour to modafinil is the compound 9
fluorenyl-S(=O)-CH2-C(=O)-(4N
a weak DAT inhibitory effect compared to modafinil
shows the effect of an electron attachment to this compound with elongation of the fluorenyl
9 carbon to S(=O) bond, very similar to t
delocalized over the fluorenyl and sulphoxide groups, with the LUMO delocalized over the 
fluorenyl group. The free energy of 
analogue in Figure 3 is estimated to
modafinil. 
 
        
Figure 3   9-fluorenyl-S(=O)-
state for dissociative electron attachment in water
 
However Dunn [8,9] reported that fluorenol which is the 9
formed from 9-Fluorenyl-S(=O)
 
where X = 4-F and Z = -(CH
-C6H5 (Figure 2) which has a high DAT binding affinity (
Ki = 3800 nM) shows the same behaviour 
Similarly substitution of the X groups in 
2 shows the same behaviour of benzylic C
.  
 
-piperazine-1N)-C(=O)-CH3 [8,9][Dunn 2012] 
 but a potent eugeroic effect. Figure 3
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ΔG
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Ki = 
---S bond 
-
which shows 
 
-
the fluorenyl 
 and the  transition 
3 itself shows a 
stronger eugeroic effect but a 59% weaker DAT binding ability than modifinil. This result is 
unusual since fluorenol is vastly structurally different from modifinil indicating a quite 
different mechanism to that of modafinil. Since the fluorene moiety can easily accommodate 
electron attachment, an investigation of electron attachment to fluorenol showed no evidence 
of bond elongation of the fluorene C9—OH bond ruling out formation of a fluorene radical 
anion species similar to that shown by 9-fluorenyl-S(=O)-CH2-C(=O)-(4N-piperazine-1N)-
C(=O)-CH3. However, an examination of electron attachment to the protonated fluorenol 
species 9-fluoreneOH2
+
 did show fluorene---OH2
+
 bond elongation as illustrated in Figure 4, 
indicating a dissociative electron attachment reaction. This proposed process may have 
validity since the brain pH varies from slightly acidic to neutral, and the brain pH 
environment is known to vary regularly with acidic surges. [24][Magnotta 2012] The 
electroreduction of the bond cleavage of the C-OH bond of 9-fluorenol has been previously 
shown to be initiated by electron transfer.[25][Mendkovich 2016] 
 
 
 
Figure 4 showing the 9-fluorenyl-S(=O)-CH2-C(=O)-(4N-piperazine-1N)-C(=O)-CH3, 9-
fluorenol and protonated 9-fluorenol 
 
Dunn 2012 [8,9] and Louvet 2012 [26] have also reported that biphenyl analogues and 
diphenylether derivative of modafinil also exhibit similar eugeroic effects  and DAT binding 
to modafinil. These compounds all possess benzylic carbon atoms adjacent to the sulphoxide 
group. Figure 5.  Both of these drugs did not show dissociative electron attachment upon 1 
electron attachment, but did show dissociation of the benzylic C---S bond upon 2 electron 
attachment. It is clear from examination of the HOMOs that the (C6H4X)2CH- and 9-
fluorenyl moieties (see Figures 1 and 2) can better stabilize electron density than can the 
benzylic moieties in Figure 5, and the TSs for CH2---S bond dissociation in these two drugs 
requires a second electron to be attached to activate the CH2---S bond. The free energy of 
activation ΔG
*
 for the water solvated ether analogue transition state shown in Figure 5 is 
estimated to be about -44 kcal/mol, which compares to the TS shown in Figure1 for modafinil 
of -30 kcal/mol. 
    
     
Figure 5 Showing biphenyl and ether analogues and transition state for two electron 
dissociative electron attachment to the ether compound. 
 
A study of the possibility of free radical species being involved in the heterocyclic piperidine 
series studied for inhibition of DAT showed as expected that electron attachment to 
compound 16A (see Table 2) did not produce any possible reactive intermediates such as 
those discussed above for the modafinil and its analogues, or fluorenyl analogues. This can be 
anticipated since the heterocyclic compounds do not have benzylic type structures that can 
stabilize electron attachment. 
 
It has been shown that diphenylmethyl p-nitrophenyl sulphide (DNPS) in dimethylformamide 
undergoes an electrochemical one-electron transfer to form the radical anion of DNPS (as 
identified by ESR spectrometry), followed by fission of the activated C–S bond to form the p-
nitrothiophenolate anion and diphenylmethyl radical. The dissociation of the radical anion is 
the rate determining step of the electrochemical processes. [27][Farnia 1978] Since the 
sulphide modafinil analogs (4b, 4c, 4d, 6a, 6b, 6c, 6d in Table 3) are known to inhibit DAT 
and show some eugeroic behaviour, it was instructive to see if these drugs also underwent 
dissociative electron attachment like the parent modifinil. It was found that (C6H5)2CH-S-
CH2C(=O)NH2 also undergoes dissociative electron attachment with elongation of the 
methine –(H)C---S bond, and the free energy of activation for the TS shown in Figure 6 is 
estimated to be -25.5 kcal/mol in water which can be compared to a value of -30 kcal/mol for 
the modafinil TS in Figure 1. The same dissociative behaviour was observed in 
dimethylformamide as in water.  
 
 
Figure 6.  Transition state for dissociative electron attachment of (C6H5)2CH-S-
CH2C(=O)NH2 in water 
Discussion 
 
The effectiveness of eugeroic drugs is dependent on the bioavailability of the drug, 
particularly its ability to enter brain cells as well as its cognition altering neurochemical 
action.  
 
The ability of modafinil analogues to cross the blood brain barrier, and bind to the DAT, has 
been examined using equations 1 and 2. The modafinil like analogues used to construct eq 1 
are closely related to modifinil itself, whereas the analogues used in eq 2 are structurally 
different, with higher proportions of saturated carbons and higher hydrophobicity or 
lipophilicity. The relative magnitudes of the coefficients in eq 1 and 2 give insights into the 
molecular factors influencing DAT binding in the two series of analogues. The three ratios 
{ΔGdesolv,CDS / ΔGlipo,CDS}, {DM / ΔGlipo,CDS}, {Volume / ΔGlipo,CDS} measure the importance 
of the molecular properties relative to hydrophobicity or lipophilicity. Eq 1 gives values of 
1.0 (-4604.8/-4588.9), 0.7 (-3244.1/-4588.9), and 0.6 (-2668.9/-4588.9) respectively, while eq 
2 gives values of 0.65 (23.2/35.6), no dependence on DM, and 0.7 (24.4/35.6) respectively. 
What is noteworthy is the change of signs for the coefficients in the two equations, showing 
that hydrophobicity has a major and opposite effect on DAT binding for modafinil like 
analogues, whereas the heterocyclic saturated analogues behave completely differently driven 
by their higher hydrophobicity. Also the heterocyclic series shows no dependency on dipole 
moment, indicating no dipole-dipole interaction between the DAT and the heterocyclic 
analogues.  This is opposite to that found for the modafinil like analogues in eq 1 where the 
substituted phenyl groups can exert significant π (di)polar effects. The larger desolvation 
ratio of 1.0 for the modafinil like analogues compared to the value of 0.65 for the 
heterocyclic analogues is also consistent with an expected stronger desolvation effect to be 
operating for the more polar modafinil like analogues in water. 
With respect to the cognition altering neurochemical action of modafinil and analogues, there 
is little systematic investigation available. The in vivo CNS activity of various modifinil like 
analogues has also been evaluated. For the series  (C6H5)2CHS(=O)CH2C(=O)NH(C6H4X) 
where X = H, 3-Cl, 4-Cl, 4-Et, 3,4-Cl, 4-NO2, 4-Br,  all these analogues were CNS 
stimulants, except where X = H. The psychological performances of mice for wakefulness, 
exploratory activity, depression and anxiogenic and anxiolytic like effects were measured. 
[28][Lari 2013] These results were similar to those previously found by De Risi for the series 
(C6H5)2CHS(=O)CH2C(=O)NH-R where R = Me, iPr, tBu were found to be stimulants, but 
where X = Et, piperidine or morpholine were found to be sedatives. For the series  
(C6H4X)2CHS(=O)CH2C(=O)NH2  where X = 4-F, 4-Cl,4-H and 4-F,4-H, these analogues 
were also found to be stimulants. These CNS activities were measured using electrically-
evoked tritiated serotonin ([
3
H]5-HT) efflux from rat cortical slices. [29][De Risi 2008] 
These in-vivo results overall suggest that substitutions at the amide N group or at the phenyl 
groups adjacent to the sulphoxide moiety have little effect on CNS activity, since the majority 
of these substitutions result in stimulatory outcomes. These observations are consistent with a 
common and dominant cognition altering neurochemical mechanism which may be 
modulated by smaller steric effects at the amide N atom.  
 
It has also been reported that modafinil exhibits antioxidant and neuroprotective properties, 
while also increasing the cortical phosphocreatine pool, and that there is evidence of the 
involvement of free radicals. [11,30][Gerrard 2007, Pierard 1995] Dimethylsulfoxide 
(DMSO) is a well known free radical scavenger, and has been recommended as a treatment 
for endotoxemia and systemic inflammatory response syndrome in horses because of its anti-
inflammatory and reactive oxygen species (ROS)–scavenging benefits. DMSO was found to 
be a scavenger of hydroxyl radicals and an effective inhibitor of platelet aggregation in an in-
vivo mouse model of pial arteriolar injury. [31,32][Rosenblum 1982, Sprayberry 2015] 
Hence there is literature evidence that sulphoxides can form free radicals. 
 
It has been shown that diphenylmethyl p-nitrophenyl sulphide (DNPS) undergoes 
electrochemical dissociative electron attachment in dimethylformamide, [27][Farnia 1978] 
which is consistent with this study which shows that the sulphide analogue of modafinil 
(C6H5)2CH-S-CH2C(=O)NH2 also undergoes the same process in water. 
 The dissociative electron attachment behaviour shown by modafinil like analogues is strongly 
indicative of a free radical mechanism for cognition altering neurochemical action of 
modafinil and analogues in the CNS. Similarly the eugeroic abilities of 9-fluorenyl 
derivatives can also be explained by a free radical mechanism. Since the modafinil like 
analogues are vastly different in structure from the 9-fluorenyl derivatives, but both have a 
common basis in that both possess benzylic carbon moieties that can form stable radicals 
which can delocalize electron density over aryl groups. 
 
The observation that 9-Fluorenyl-S(=O)-CH2-C(=O)-(4N-piperazine-1N)-C(=O)-CH3 which 
has been shown to exert a potent eugeroic effect but is a weak inhibitor of DAT shows a 
strong dissociation of the C9---S bond upon electron attachment is indicative of a free radical 
eugeroic effect that is largely independent of acting as a dopamine reuptake inhibitor. 
Previous structure activity studies of modafinil analogues found that DAT inhibition did not 
correlate with wakefulness-promoting effects in animals, and a number of analogues without 
any significant inhibition of the DAT still produced wakefulness-promoting effects. 
[8,9][Dunn 2012] 
 
Conclusions 
 
A structure activity model which incorporates the desolvation, lipophilicity, dipole moment 
moment and molecular volume of a series of modafinil like analogues has been compared to 
a series of saturated heterocyclic analogues in their ability to inhibit the dopamine transporter 
(DAT). It has been found that hydrophilicity or lipophilicity has a larger inhibitory effect for 
the heterocyclic analogues than the modafinil like analogues, but the heterocyclic inhibitors 
show no dependence on dipole moment unlike the modafinil like analogues. The modafinil 
like analogues have a higher desolvation requirement than the heterocyclic analogues prior to 
binding with DAT as expected for the more polar structures. 
 
Evidence is presented that strongly implicates the involvement of free radical species in the 
eugeroic ability of modafinil like and 9-fluorene analogues via a dissociative electron 
attachment mechanism. This eugeroic ability is largely separate from a DAT inhibition 
mechanism. 
 
Experimental 
 
All calculations were carried out using the Gaussian 09 package. Energy optimisations were 
at the DFT/B3LYP/6-31G(d,p) (6d, 7f) level of theory for all atoms. Selected optimisations at 
the DFT/B3LYP/6-311
+
G(d,p) (6d, 7f) level of theory gave very similar results to those at the 
lower level. Optimized structures were checked to ensure energy minima were located, with 
no negative frequencies. Energy calculations were conducted at the DFT/B3LYP/6-31G(d,p) 
(6d, 7f) level of theory with optimised geometries in water, using the IEFPCM/SMD solvent 
model. With the 6-31G(d) basis set, the SMD model achieves mean unsigned errors of 0.6 - 
1.0 kcal/mol in the solvation free energies of tested neutrals and mean unsigned errors of 4 
kcal/mol on average for ions. [33][Marenich 2009] The 6-31G(d,p) basis set has been used to 
calculate absolute free energies of solvation and compare these data with experimental results 
for more than 500 neutral and charged compounds. The calculated values were in good 
agreement with experimental results across a wide range of compounds. [34,35][Rayne 2010, 
Rizzo 2006] Adding diffuse functions to the 6-31G* basis set (ie 6-31
+
G**) had no 
significant effect on the solvation energies with a difference of less than 1% observed in 
solvents, which is within the literature error range for the IEFPCM/SMD solvent model. 
HOMO and LUMO calculations included both delocalized and localized orbitals (NBO). 
 
The ease of bond cleavage of the benzylic methine C---S bond of modafinil by dissociative 
electron attachment was confirmed by observing that this process occurs in the gas phase as 
well as in water. The electron impact mass spectrometry study of modafinil gives the main 
ionization fragmentation pathway involving a fragment m/e of 167, ie the (C6H5)2CH ion. 
[36][Dubey 2009] 
 
It is noted that high computational accuracy for each species in different environments is not 
the focus of this study, but comparative differences between various species is the aim of the 
study. The literature values for DAT Ki used in the multiple regression LFER equations have 
much higher experimental uncertainties than the calculated molecular properties. The 
statistical analyses include the multiple correlation coefficient R
2
, the F test of significance, 
standards errors for the estimates (SEE) and each of the variables SE(ΔGdesolCDS), 
SE(ΔGlipoCDS), SE(Dipole Moment), SE (Molecular Volume), as calculated from “t” 
distribution statistics. Residual analysis was used to identify outliers.  
 
Racemic mixtures of modafinil like analogues (Table 1, using the same nomenclature as Cao 
2011 [2]) were evaluated for DAT binding at the rat brain membrane, Ki (nM). 
Synaptosomal competitive binding of heterocyclic and nocaine analogues (tested as the free 
base) and [
3
H]dopamine by striatum rat brain DAT at pH 7.4 and 37C, Ki (nM). Table 2 
shows the analogues evaluated, using the same nomenclature as Zhou 2004. [1]  
Table 3 shows the DAT binding data Ki for modafinil and piperidine analogues and the 
calculated molecular properties in water. 
 
 
Table 1.   Modafinil analogues DAT inhibitors [2][Cao 2011] 
 
 
 
Compound X,Y,Z,R,R’ Substituents 
(+/-) Modafinil H,O,O,H,H 
4b F,-,O,H,H 
4c Cl,-,O,H,H 
4d Br,-,O,H,H 
5b F,O,O,H,H 
5c Cl,O,O,H,H 
5d Br,O,O,H,H 
6a H,-,O,Me,Me 
6b F,-,O,Me,Me 
6c Cl,-,O,Me,Me 
6d Br,-,O,Me,Me 
7c Cl,O,O,Me,Me 
7d Br,O,O,Me,Me 
7f Cl,O,O,Me,H 
7g Br,O,O,Me,H 
7h H,O,O,H,(CH2)3C6H5 
9a H,O,H,H,(CH2)3C6H5 
9d Cl,O,H,Me,Me 
Cocaine  
  
 
 
Table 2.   Heterocyclic DAT Inhibitors [1][Zhou 2004] 
 
 
 
Compound 
Ar = (p-Cl)-C6H4 
X Y Z n 
1(+) CPCA     
4 -OH    
5 -I    
6 -OMe   n=0 
7 -OMe   n=1 
8   -OH n=0 
9   -OH n=1 
10   -OMe n=0 
11   -OMe n=1 
12   -OC(=O)Me n=0 
13   -OC(=O)Me n=1 
14   -OC(=O)C6H5 n=0 
15   -OC(=O)C6H5 n=1 
16(a)  -NH2  n=0 
16(b)  -NH(OH)  n=0 
16(c)  -NH(Me)  n=0 
16(d)  -NMe2  n=0 
16(e)  -NH(iPr)  n=0 
16(f)  -N(-CH2-)5  n=0 
17(a)  -NH2  n=1 
17(b)  -NH(OH)  n=1 
17(c)  -NH(Me)  n=1 
17(d)  -NMe2  n=1 
17(e)  -NH(iPr)  n=1 
17(f)  -N(-CH2-)5  n=1 
18    n=0 
19    n=1 
20     
21    n=0 
22    n=1 
 
 
 
 
Table 3.  DAT binding data Ki for modafinil and piperidine analogues and calculated 
molecular properties in water 
 
 
DAT  Ki 
nM 
ΔGCDS,w  
kcal/mol 
ΔGCDS,o  
 kcal/mol 
Dipole 
Moment 
D 
Molec 
Volume 
cm3/mol 
Cao 2011 
Structures in 
Table 1 
     (+/-) 
Modafinil 2520 5.98 -6.59 3.7 226 
4B 1570 7.59 -5.39 4.84 184 
4C 2230 6.37 -7.6 5.41 200 
4D 1930 4.8 -9.22 5.28 270 
5B 2190 7.34 -5.29 3.65 231 
5C 919 6.11 -7.42 3.81 259 
5D 600 4.53 -9.06 3.74 272 
6A 16500 6.91 -8.3 4.82 220 
6B 9150 8.33 -7 5.12 200 
6C 4510 6.94 -9.05 5.87 235 
6D 2450 5.39 -10.68 6.05 231 
7C 34600 6.98 -8.96 3.27 222 
7D 21300 5.34 -10.59 3.52 282 
7F 24440 6.55 -8.28 4.34 208 
7G 1650 4.98 -9.92 4.38 262 
7H 26660 8.09 -11.73 4.38 261 
9A 194 6.03 -11.24 6.78 316 
7H 26660 8.09 -11.73 4.38 261 
9A 194 6.03 -11.24 6.78 316 
9D 2890 3.5 -8.56 3.77 231 
Cocaine 71.8 6.16 -6.8 0.95 159 
11B* 2.5 5.85 -11.78 4.55 465 
Zhou 
2004 
Structures in 
Table 2 
     Modafinil 3800 5.98 -6.59 3.7 226 
Cocaine 423 6.16 -6.8 0.95 159 
CPCA 233 4.06 -5.85 6.69 175 
Z4 497 1.96 -6.05 5.24 201 
Z5 376 1.43 -5.13 4.66 223 
Z6 80 4.76 -7.36 3.32 246 
Z7 231 4.77 -7.23 6.37 279 
Z8 16 2.84 -7.63 3.11 233 
Z9 12 2.78 -7.53 7.33 221 
Z10 50 3.72 -7.31 3.08 230 
Z11 15 3.68 -7.22 7.31 216 
Z12 35 4.99 -8.31 6.25 242 
Z13 9 4.93 -8.22 9.65 303 
Z14 68 5.81 -10.83 6.54 342 
Z15 32 5.74 -10.7 9.84 284 
Z16A 159 3.68 -6.76 5.33 263 
Z16B 85 5.05 -7.47 5.67 247 
Z16C 13 3.47 -7.65 4.77 255 
Z16D 116 3.94 -8.23 5.08 264 
Z16E 1 4.93 -8.98 4.82 282 
Z16F 83 3.74 -10.2 5.33 286 
Z17A 209 3.76 -6.66 7.2 212 
Z17B 55 5.09 -7.4 7.18 257 
Z17C 164 3.63 -7.6 5.75 235 
Z17D 2884 4.08 -8.06 6.89 224 
Z17E 248 4.89 -8.78 6.45 278 
Z17F 379 3.8 -10.07 7.09 340 
Z18 126 2.17 -7.89 4.78 175 
Z19 1653 2.48 -7.87 7.33 229 
Z20 51 4.97 -6.46 9.37 246 
Z21 114 3.78 -6.08 5.56 191 
Z22 108 3.85 -6 7.66 201 
      Footnote:  Compound 11B from Cao 2016 [3] 
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